New radiotherapy method tested in breast cancer that has spread to the brain
Tests a new radiation method in adults with breast cancer spread to the brain.
Plain-language title generated from the registry record
Registry title: BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
Key facts
- Where
- London and Oxford, United KingdomSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 100 years old?
Source: NCT06611306, who can take part
Where in United Kingdom
- Imperial College LondonLondon, United KingdomTaking people
- University of Oxford Cancer and Haematology Centre | Churchill Hospital Headington, Oxford,Oxford, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Imperial College London
- Trial code
- NCT06611306
- Record updated
- 8 October 2026
- Original description
The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast cancer has spread to the brain (brain metastases) at 8 weeks post enrolling into the study.Read full original descriptionShow less
BEAT-Breast - Improving Outcomes for Breast Cancer Patients With Brain Metastases: a Pilot Nonrandomised Single Arm Phase 2 Clinical Trial in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy
The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast cancer has spread to the brain (brain metastases) at 8 weeks post enrolling into the study.
The main questions that have been set out to to answer are:
* Is it possible to deliver the novel radiotherapy approach, DE-iPTV? * Is it possible to measure health -related quality of life? * What impact does the novel radiotherapy approach have on: patient's quality of life, control of the brain metastasis (control of the lesion) and steroid use?
Participants will:
* Receive 5 doses of radiotherapy * Complete weekly quality of life (EQ-5D) assessments and medication (steroid) diaries (via telephone/ postal) until 12 weeks post enrolment * Be reviewed in clinic with up-to-date MRI scans at 8, 12 and 24 weeks post-enrolment * Complete a more detailed HRQoL panel of assessments will be assessed at baseline, 8 weeks, 12 weeks and 24 weeks post enrolment.
Inclusion: Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up; Adult (aged 16+) patients, resident in the United Kingdom; Histologically confirmed primary breast cancer with brain metastases on MRI imaging; The treating oncologist considers whole-brain radiotherapy to be the most suitable treatment outside of the trial; Eastern Cooperative Oncology Group Performance status 0, 1 or 2; Able to respond to question about their quality of life, symptoms, and side effects remotely (via telephone assessments; Life expectancy from extra-cranial disease >3 months.
Exclusion: Previous whole or partial brain radiotherapy (previous surgery or SRS is acceptable); Plan for hippocampal-sparing whole brain radiotherapy; Leptomeningeal disease; Unable to complete a brain MRI and/or known allergy to gadolinium; "Miliary" pattern of metastases: patients with over 15 metastases are excluded (clinician-based assessment); Cystic metastases; Unable to give informed consent; Prognosis less than 3 months; Pregnant or nursing women.